Protein profiling in intensive care unit-treated COVID-19 patients identifies biomarkers of residual lung abnormalities
(2025) In ERJ open research 11(3). p.1-13- Abstract
BACKGROUND: In this study, we combine proteomics with functional parameters and imaging to examine potential biomarkers that may identify patients at risk of developing persistent lung sequelae following coronavirus disease 2019 (COVID-19).
METHODS: We performed multiplex profiling of serum and collected clinical data from intensive care unit (ICU)-treated patients with COVID-19 (n=43) at 4 and 10 months post hospitalisation.
RESULTS: Four months post discharge, patients with COVID-19 demonstrated lower % predicted forced vital capacity (72.2%
versus 113% (p<0.0001)) and % predicted forced expiratory volume in 1 s (74.5%
versus 103% (p<0.0001)) compared with healthy controls. A persistent upregulation (
... (More)BACKGROUND: In this study, we combine proteomics with functional parameters and imaging to examine potential biomarkers that may identify patients at risk of developing persistent lung sequelae following coronavirus disease 2019 (COVID-19).
METHODS: We performed multiplex profiling of serum and collected clinical data from intensive care unit (ICU)-treated patients with COVID-19 (n=43) at 4 and 10 months post hospitalisation.
RESULTS: Four months post discharge, patients with COVID-19 demonstrated lower % predicted forced vital capacity (72.2%
versus 113% (p<0.0001)) and % predicted forced expiratory volume in 1 s (74.5%
versus 103% (p<0.0001)) compared with healthy controls. A persistent upregulation (
versus healthy controls) of inflammatory and remodelling factors, including among others, Galectin-1 (Gal-1), C-X-C motif chemokine 13 (CXCL13), monocyte chemoattractant protein 3 (MCP-3) and matrix metalloproteinase 7 (MMP7), were observed. Patients with moderate to severe parenchymal involvement (>5% of lung tissue) on high-resolution computed tomography (HRCT) had higher levels of the proteins lysosomal associated membrane protein-3 (LAMP3) and MMP7 compared with patients with minor (<5%) or no findings on HRCT. Both proteins demonstrated consecutive associations to lung function and parenchymal involvement. Histological evaluation of LAMP3 in lung tissue confirmed LAMP3 localisation to alveolar type 2 cells in more preserved areas of the parenchyma. However, areas of remodelling were devoid of LAMP3 concurrent with the appearance of KRT5+ and KRT17+ basal cells.
CONCLUSION: Despite functional and radiological improvements following COVID-19, persistent upregulation of inflammation and remodelling factors were observed. Similarities in the expression of LAMP3 in COVID-19 and idiopathic pulmonary fibrosis may suggest it as a potential biomarker for chronic lung damage.
(Less)
- author
- organization
- publishing date
- 2025-05
- type
- Contribution to journal
- publication status
- published
- subject
- in
- ERJ open research
- volume
- 11
- issue
- 3
- pages
- 1 - 13
- publisher
- European Respiratory Society
- external identifiers
-
- scopus:105009073540
- pmid:40551787
- ISSN
- 2312-0541
- DOI
- 10.1183/23120541.00981-2024
- language
- English
- LU publication?
- yes
- additional info
- Copyright ©The authors 2025.
- id
- a90f6a41-90c9-48ee-941b-27cc6776360e
- date added to LUP
- 2025-06-30 16:30:10
- date last changed
- 2025-07-07 04:02:16
@article{a90f6a41-90c9-48ee-941b-27cc6776360e, abstract = {{<p>BACKGROUND: In this study, we combine proteomics with functional parameters and imaging to examine potential biomarkers that may identify patients at risk of developing persistent lung sequelae following coronavirus disease 2019 (COVID-19).</p><p>METHODS: We performed multiplex profiling of serum and collected clinical data from intensive care unit (ICU)-treated patients with COVID-19 (n=43) at 4 and 10 months post hospitalisation.</p><p>RESULTS: Four months post discharge, patients with COVID-19 demonstrated lower % predicted forced vital capacity (72.2%<br> versus 113% (p<0.0001)) and % predicted forced expiratory volume in 1 s (74.5%<br> versus 103% (p<0.0001)) compared with healthy controls. A persistent upregulation (<br> versus healthy controls) of inflammatory and remodelling factors, including among others, Galectin-1 (Gal-1), C-X-C motif chemokine 13 (CXCL13), monocyte chemoattractant protein 3 (MCP-3) and matrix metalloproteinase 7 (MMP7), were observed. Patients with moderate to severe parenchymal involvement (>5% of lung tissue) on high-resolution computed tomography (HRCT) had higher levels of the proteins lysosomal associated membrane protein-3 (LAMP3) and MMP7 compared with patients with minor (<5%) or no findings on HRCT. Both proteins demonstrated consecutive associations to lung function and parenchymal involvement. Histological evaluation of LAMP3 in lung tissue confirmed LAMP3 localisation to alveolar type 2 cells in more preserved areas of the parenchyma. However, areas of remodelling were devoid of LAMP3 concurrent with the appearance of KRT5+ and KRT17+ basal cells.<br> </p><p>CONCLUSION: Despite functional and radiological improvements following COVID-19, persistent upregulation of inflammation and remodelling factors were observed. Similarities in the expression of LAMP3 in COVID-19 and idiopathic pulmonary fibrosis may suggest it as a potential biomarker for chronic lung damage.</p>}}, author = {{Kalafatis, Dimitrios and Björnson, Mikael and Svobodová, Barbora and Kistner, Anna and Nygren-Bonnier, Malin and Runold, Michael and Bruchfeld, Judith and Wheelock, Åsa and Dellgren, Göran and Elowsson, Linda and Westergren-Thorsson, Gunilla and Sköld, Magnus}}, issn = {{2312-0541}}, language = {{eng}}, number = {{3}}, pages = {{1--13}}, publisher = {{European Respiratory Society}}, series = {{ERJ open research}}, title = {{Protein profiling in intensive care unit-treated COVID-19 patients identifies biomarkers of residual lung abnormalities}}, url = {{http://dx.doi.org/10.1183/23120541.00981-2024}}, doi = {{10.1183/23120541.00981-2024}}, volume = {{11}}, year = {{2025}}, }